share_log

Cantor Fitzgerald Reiterates Overweight on Alpha Tau Medical, Maintains $23 Price Target

Cantor Fitzgerald Reiterates Overweight on Alpha Tau Medical, Maintains $23 Price Target

坎託·菲茨傑拉德重申增持 Alpha Tau Medical,維持23美元的目標股價
Benzinga ·  2023/08/29 10:24

Cantor Fitzgerald analyst Kristen Kluska reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Overweight and maintains $23 price target.

Cantor Fitzgerald分析師Kristen Kluska重申Alpha Tau Medical(納斯達克:DRTS)增持,並維持23美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論